Mostrar el registro sencillo del ítem

Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach

dc.rights.licenseopenen_US
dc.contributor.authorWESKAMM, Leonie M
dc.contributor.authorTARNOW, Paulina
dc.contributor.authorHARMS, Charlotte
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHUCHON, Melanie
dc.contributor.authorRAADSEN, Matthijs P
dc.contributor.authorFRIEDRICH, Monika
dc.contributor.authorRUBENACKER, Laura
dc.contributor.authorGRUTTNER, Cordula
dc.contributor.authorGARCIA, Mariana G
dc.contributor.authorKOCH, Till
dc.contributor.authorBECKER, Stephan
dc.contributor.authorSUTTER, Gerd
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLHOMME, Edouard
dc.contributor.authorHAAGMANS, Bart L
dc.contributor.authorFATHI, Anahita
dc.contributor.authorBLOIS, Sandra M
dc.contributor.authorDAHLKE, Christine
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRICHERT, Laura
dc.contributor.authorADDO, Marylyn M
dc.date.accessioned2024-10-16T08:58:25Z
dc.date.available2024-10-16T08:58:25Z
dc.date.issued2024-08-16
dc.identifier.issn2589-0042en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/202529
dc.description.abstractEnBesides neutralizing antibodies, which are considered an important measure for vaccine immunogenicity, Fc-mediated antibody functions can contribute to antibody-mediated protection. They are strongly influenced by structural antibody properties such as subclass and Fc glycan composition. We here applied a systems serology approach to dissect humoral immune responses induced by MVA-MERS-S, an MVA-vectored vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV). Building on preceding studies reporting the safety and immunogenicity of MVA-MERS-S, our study highlights the potential of a late boost, administered one year after prime, to enhance both neutralizing and Fc-mediated antibody functionality compared to the primary vaccination series. Distinct characteristics were observed for antibodies specific to the MERS-CoV spike protein S1 and S2 subunits, regarding subclass and glycan compositions as well as Fc functionality. These findings highlight the benefit of a late homologous booster vaccination with MVA-MERS-S and may be of interest for the design of future coronavirus vaccines.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enCell biology
dc.subject.enImmune response
dc.subject.enImmunology
dc.subject.enVirology
dc.title.enDissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach
dc.title.alternativeiScienceen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.isci.2024.110470en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39148710en_US
bordeaux.journaliScienceen_US
bordeaux.page110470en_US
bordeaux.volume27en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue8en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=iScience&rft.date=2024-08-16&rft.volume=27&rft.issue=8&rft.spage=110470&rft.epage=110470&rft.eissn=2589-0042&rft.issn=2589-0042&rft.au=WESKAMM,%20Leonie%20M&TARNOW,%20Paulina&HARMS,%20Charlotte&HUCHON,%20Melanie&RAADSEN,%20Matthijs%20P&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BPH_iScience_2024_Weskamm.pdf
Tamaño:
4.015Mb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
914bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem